glp-1 dpp 4 Glucagon-like peptide-1 Cellular Sites and Mechanisms Linking
Description
GLP-1 receptor agonist and non-alcoholic fatty liver disease
Prevalence of overweight, obesity, and extreme obesity among adults: united states, trends 19601962 through 20092010 (2019)
Why Personalization Matters GLP-1 therapy has well-known side effects, the most common being nausea, particularly during the first 4 to 8 weeks of dose titration
[DOI] [PubMed] [Google Scholar] 33.Jimnez-Cortegana C., Garca-Galey A., Tami M., et al
10.1038/ajg.2010.363 39 KessokuT.KobayashiT.ImajoK.TanakaK.YamamotoA.TakahashiK.et al (2021)
